{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:59:09Z","timestamp":1767193149514,"version":"3.48.0"},"reference-count":36,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"crossref","award":["01KG2403"],"award-info":[{"award-number":["01KG2403"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,7,14]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Alcohol dependence (AD) is highly prevalent and has severe consequences on health and quality of life. However, the efficacy of approved pharmacotherapies such as naltrexone (NTX) remains limited, highlighting the need for novel pharmacotherapeutic approaches. Cannabidiol (CBD) is a promising candidate, which has shown potential to reduce craving and alcohol use by modulating brain circuits involved in craving and addiction. Preclinical studies suggest that CBD may enhance NTX\u2019s therapeutic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a three-armed, randomised, double-blind, placebo-controlled parallel group, multicentre phase II clinical trial. A total of 150 patients with AD will be randomised (1:1:1) to receive either 800\u2009mg or 1200\u2009mg CBD plus 50\u2009mg oral NTX or placebo plus 50\u2009mg oral NTX for 14 days. Alcohol craving will be assessed using the Obsessive Compulsive Drinking Scale (OCDS-G) where the primary endpoint is the change from baseline to the end of treatment. Secondary outcomes include craving during the entire study, quality of life, depressive symptoms, anxiety, patient-reported outcomes, neural brain activation, CBD plasma levels, time to relapse, alcohol use and treatment safety. For the comparison of each experimental group to the control group, a strata-adjusted (centre and baseline OCDS-G) van Elteren test is applied with adjustment for multiple testing by Bonferroni-Holm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The trial has been approved by the Ethics Committee and the competent authority (ID: B_03510). All participants will provide written informed consent. An independent Data and Safety Monitoring Board will monitor safety. This trial complies with national and international regulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06845124\">NCT06845124<\/jats:ext-link>\n                      ; EU Trial Number: 2024-518164-12-00.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-106348","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T04:30:42Z","timestamp":1755059442000},"page":"e106348","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Investigation of the combined effects of cannabidiol plus naltrexone on alcohol craving in alcohol dependence: study protocol of a phase II randomised, double-blind, placebo-controlled, parallel-group trial \u2013 ICONICplus Trial"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06845124","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9122-5197","authenticated-orcid":false,"given":"Sina","family":"Vetter","sequence":"first","affiliation":[{"name":"Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Heidelberg University Medical Faculty, Mannheim, Germany"},{"name":"German Center for Mental Health, Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Weinberg","sequence":"additional","affiliation":[{"name":"Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Heidelberg University Medical Faculty, Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina C","family":"Thomas","sequence":"additional","affiliation":[{"name":"Coordination Centre for Clinical Trials (KKS), University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0294-2483","authenticated-orcid":false,"given":"Marietta","family":"Kirchner","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry (IMBI), University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Thalmann","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry (IMBI), University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Klose","sequence":"additional","affiliation":[{"name":"Institute of Medical Biometry (IMBI), University Hospital Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlen","family":"Pfisterer","sequence":"additional","affiliation":[{"name":"Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Heidelberg University Medical Faculty, Mannheim, Germany"},{"name":"German Center for Mental Health, Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten","family":"K\u00f6lsch","sequence":"additional","affiliation":[{"name":"Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Heidelberg University Medical Faculty, Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Oesterle","sequence":"additional","affiliation":[{"name":"Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Heidelberg University Medical Faculty, Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Vollstaedt-Klein","sequence":"additional","affiliation":[{"name":"Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Heidelberg University Medical Faculty, Mannheim, Germany"},{"name":"German Center for Mental Health, Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Koopmann","sequence":"additional","affiliation":[{"name":"Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Heidelberg University Medical Faculty, Mannheim, Germany"},{"name":"Feuerlein Center on Translational Addiction Medicine (FCTS), Heidelberg University, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Lenz","sequence":"additional","affiliation":[{"name":"Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Heidelberg University Medical Faculty, Mannheim, Germany"},{"name":"German Center for Mental Health, Mannheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falk","family":"Kiefer","sequence":"additional","affiliation":[{"name":"Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Heidelberg University Medical Faculty, Mannheim, Germany"},{"name":"German Center for Mental Health, Mannheim, Germany"},{"name":"Feuerlein Center on Translational Addiction Medicine (FCTS), Heidelberg University, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Link","sequence":"additional","affiliation":[{"name":"Feuerlein Center on Translational Addiction Medicine (FCTS), Heidelberg University, Heidelberg, Germany"},{"name":"Department of Addiction Treatment and Rehabilitation, Psychiatric Center North Baden, Wiesloch, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Bach","sequence":"additional","affiliation":[{"name":"Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Heidelberg University Medical Faculty, Mannheim, Germany"},{"name":"German Center for Mental Health, Mannheim, Germany"},{"name":"Feuerlein Center on Translational Addiction Medicine (FCTS), Heidelberg University, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"2025123106464058000_15.8.e106348.1","doi-asserted-by":"publisher","DOI":"10.1037\/0003-066X.41.7.765"},{"key":"2025123106464058000_15.8.e106348.2","doi-asserted-by":"crossref","unstructured":"R\u00f6sner S , Hackl-Herrwerth A , Leucht S , et al . Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010;CD001867. doi:10.1002\/14651858.CD001867.pub3","DOI":"10.1002\/14651858.CD001867.pub3"},{"key":"2025123106464058000_15.8.e106348.3","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr4090"},{"key":"2025123106464058000_15.8.e106348.4","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/s41386-018-0050-8","article-title":"Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle","volume":"43","author":"Gonzalez-Cuevas","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"2025123106464058000_15.8.e106348.5","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12495"},{"key":"2025123106464058000_15.8.e106348.6","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1111\/bph.14380","article-title":"Effects of cannabidiol plus naltrexone on motivation and ethanol consumption","volume":"175","author":"Viudez-Mart\u00ednez","year":"2018","journal-title":"Br J Pharmacol"},{"key":"2025123106464058000_15.8.e106348.7","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.18101191"},{"key":"2025123106464058000_15.8.e106348.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2009.01074.x"},{"key":"2025123106464058000_15.8.e106348.9","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0373-7"},{"key":"2025123106464058000_15.8.e106348.10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1037\/adb0000706","article-title":"THC and CBD effects on alcohol use among alcohol and cannabis co-users","volume":"35","author":"Karoly","year":"2021","journal-title":"Psychol Addict Behav"},{"key":"2025123106464058000_15.8.e106348.11","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","article-title":"Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial","volume":"7","author":"Freeman","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"2025123106464058000_15.8.e106348.12","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2025123106464058000_15.8.e106348.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"2025123106464058000_15.8.e106348.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.004"},{"key":"2025123106464058000_15.8.e106348.15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-059672","article-title":"ON-ICE trial: Investigation of the combined effects of oxytocin and naltrexone on stress-induced and alcohol cue-induced craving in alcohol use disorder-Study protocol of a phase II randomised double-blind placebo-controlled parallel-group trial","volume":"12","author":"Zimmermann","year":"2022","journal-title":"BMJ Open"},{"key":"2025123106464058000_15.8.e106348.16","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/s41380-024-02869-y","article-title":"Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial","volume":"30","author":"Zimmermann","year":"2025","journal-title":"Mol Psychiatry"},{"key":"2025123106464058000_15.8.e106348.17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40429-020-00326-8","article-title":"Therapeutic Efficacy of Cannabidiol (CBD): A Review of the Evidence from Clinical Trials and Human Laboratory Studies","volume":"7","author":"Sholler","year":"2020","journal-title":"Curr Addict Rep"},{"key":"2025123106464058000_15.8.e106348.18","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/acer.13964","article-title":"Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review","volume":"43","author":"Turna","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"key":"2025123106464058000_15.8.e106348.19","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000118"},{"key":"2025123106464058000_15.8.e106348.20","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12717","article-title":"Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone","volume":"25","author":"Bach","year":"2020","journal-title":"Addict Biol"},{"key":"2025123106464058000_15.8.e106348.21","unstructured":"Fachgesellschaften: fh, deutsche gesellschaft f\u00fcr psychiatrie und psychotherapie pund, (dg-sucht) dgfrsusev. s3-leitlinie \u201escreening, diagnose und behandlung alkoholbezogener st\u00f6rungen. 2020. Available: https:\/\/wwwawmforg\/leitlinien\/detail\/ll\/076-001html"},{"key":"2025123106464058000_15.8.e106348.22","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agh073"},{"key":"2025123106464058000_15.8.e106348.23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.15288\/jsa.2003.64.120","article-title":"Alcohol craving predicts drinking during treatment: an analysis of three assessment instruments","volume":"64","author":"Flannery","year":"2003","journal-title":"J Stud Alcohol"},{"key":"2025123106464058000_15.8.e106348.24","doi-asserted-by":"publisher","DOI":"10.1037\/\/0033-2909.111.2.361"},{"key":"2025123106464058000_15.8.e106348.25","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1521-4036(200001)42:1<17::AID-BIMJ17>3.0.CO;2-U"},{"key":"2025123106464058000_15.8.e106348.26","doi-asserted-by":"publisher","DOI":"10.1177\/0962280206074463"},{"key":"2025123106464058000_15.8.e106348.27","doi-asserted-by":"crossref","unstructured":"R\u00f6sner S , Hackl-Herrwerth A , Leucht S , et al . Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010. doi:10.1002\/14651858.CD001867.pub3","DOI":"10.1002\/14651858.CD001867.pub3"},{"key":"2025123106464058000_15.8.e106348.28","unstructured":"American Psychiatric Association . Diagnostic and statistical manual of mental disorders IV. 4th edn. Washington, DC2000, 2000."},{"key":"2025123106464058000_15.8.e106348.29","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association . Diagnostic and statistical manual of mental disorders: DSM-5. Washington, DC: American psychiatric association, 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2025123106464058000_15.8.e106348.30","doi-asserted-by":"crossref","unstructured":"Miller WR . Form 90: a structured assessment interview for drinking and related behaviors: test manual. 1996.","DOI":"10.1037\/e563242012-001"},{"key":"2025123106464058000_15.8.e106348.31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.15288\/jsad.2009.70.689","article-title":"A validation study of the alcohol dependence scale","volume":"70","author":"Doyle","year":"2009","journal-title":"J Stud Alcohol Drugs"},{"key":"2025123106464058000_15.8.e106348.32","unstructured":"Bleich S-R . FTNA: Fagerstr\u00f6m-Test F\u00fcr Nikotinab\u00e4ngigkeit. G\u00f6ttingen: Beltz Test, 2002."},{"key":"2025123106464058000_15.8.e106348.33","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3932(71)90067-4"},{"key":"2025123106464058000_15.8.e106348.34","unstructured":"Hautzinger MK , K\u00fchner C , Beck AT . Beck depressions-inventar: BDI II. Frankfurt am Main: Pearson Assessment, 2009."},{"key":"2025123106464058000_15.8.e106348.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1995.tb01554.x"},{"key":"2025123106464058000_15.8.e106348.36","unstructured":"World Health Organization. Division of mental h . WHOQOL-BREF: introduction, administration, scoring and generic version of the assessment: field trial version. Geneva World Health Organization; 1996."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-106348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:48:07Z","timestamp":1767192487000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-106348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,12]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjopen-2025-106348"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-106348","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}